Table S3 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations

Aoki, Kazunori; Nishito, Yukari; Motoi, Noriko; Arai, Yasuhito; Hiraoka, Nobuyoshi; Shibata, Tatsuhiro; Sonobe, Yukiko; Kayukawa, Yoko; Hashimoto, Eri; Takahashi, Mina; Fujii, Etsuko; Nishizawa, Takashi; Fukuda, Hironori; Ohashi, Kana; Arai, Kosuke; Mizoguchi, Yukihiro; Yoshida, Yukihiro; Watanabe, Shun-ichi; Yamashita, Makiko; Kitano, Shigehisa; Sakamoto, Hiromi; Nagata, Yuki; Mitsumori, Risa; Ozaki, Kouichi; Niida, Shumpei; Kanai, Yae; Hirayama, Akiyoshi; Soga, Tomoyoshi; Maruyama, Toru; Tsukada, Keisuke; Yabuki, Nami; Shimada, Mei; Kitazawa, Takehisa; Natori, Osamu; Sawada, Noriaki; Kato, Atsuhiko; Yoshida, Teruhiko; Yasuda, Kazuki; Mizuno, Hideaki; Tsunoda, Hiroyuki; Ochiai, Atsushi

doi:10.1158/2767-9764.23508961.v1

crc-22-0415-s20.pdf (225.05 kB)

Table S3 from Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic Alterations

journal contribution

posted on 2023-06-13, 14:20 authored by Kazunori Aoki, Yukari Nishito, Noriko Motoi, Yasuhito Arai, Nobuyoshi Hiraoka, Tatsuhiro Shibata, Yukiko Sonobe, Yoko Kayukawa, Eri Hashimoto, Mina Takahashi, Etsuko Fujii, Takashi Nishizawa, Hironori Fukuda, Kana Ohashi, Kosuke Arai, Yukihiro Mizoguchi, Yukihiro Yoshida, Shun-ichi Watanabe, Makiko Yamashita, Shigehisa Kitano, Hiromi Sakamoto, Yuki Nagata, Risa Mitsumori, Kouichi Ozaki, Shumpei Niida, Yae Kanai, Akiyoshi Hirayama, Tomoyoshi Soga, Toru Maruyama, Keisuke Tsukada, Nami Yabuki, Mei Shimada, Takehisa Kitazawa, Osamu Natori, Noriaki Sawada, Atsuhiko Kato, Teruhiko Yoshida, Kazuki Yasuda, Hideaki Mizuno, Hiroyuki Tsunoda, Atsushi Ochiai

Antibodies for IHC

Funding

Japan Agency for Medical Research and Development (AMED)

National Cancer Center Japan (NCC)

MEXT | Japan Society for the Promotion of Science (JSPS)

History

ARTICLE ABSTRACT

The precise TIL profiling classified NSCLC into novel three immune subtypes that correlates with patient outcome, identifying subtype-specific molecular pathways and genomic alterations that should play important roles in constructing subtype-specific immune tumor microenvironments. These classifications of NSCLC based on TIL status are useful for developing personalized immune therapies for NSCLC.